Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povidone-iodine gargling for reduction of salivary SARS-CoV-2
jRCT1051200078Completed
- Sponsor
- Osaka Prefectural Hospital Organization
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of povidone-iodine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Osaka Prefectural Hospital Organization. Primary endpoint: Negative rate of SARS-CoV-2 by RT-PCR in saliva on day 5. Started Nov 2020; status: completed.
02
Drugs
povidone-iodine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1051200078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051200078.